ARWR beat EPS expectations by 1461.39%
May 12, 2025, 10:33 PM
0.00%
What does ARWR do
Arrowhead Pharmaceuticals, based in Pasadena, California, develops RNA-based therapies targeting intractable diseases, employing 525 staff and featuring 14 clinical-stage investigational medicines across various therapeutic areas. Their TRiMTM platform enables tissue-specific delivery through RNA interference mechanisms.
Arrowhead Pharmaceuticals (ARWR) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Arrowhead Pharmaceuticals's actual EPS was $2.75, beating the estimate of -$0.20 per share, resulting in a 1461.39% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.